Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics

J Mol Graph Model. 2021 Jul:106:107931. doi: 10.1016/j.jmgm.2021.107931. Epub 2021 May 10.

Abstract

The HIV-1 protease is an important drug target in antiretroviral therapy due to the crucial role it plays in viral maturation. A greater understanding of the dynamics of the protease as a result of drug-induced mutations has been successfully elucidated using computational models in the past. We performed induced-fit docking studies and molecular dynamics simulations on the wild-type South African HIV-1 subtype C protease and two non-active site mutation-containing protease variants; HP3 PR and HP4 PR. The HP3 PR contained the I13V, I62V, and V77I mutations while HP4 PR contained the same mutations with the addition of the L33F mutation. The simulations were initiated in a cubic cell universe containing explicit solvent, with the protease variants beginning in the fully closed conformation. The trajectory for each simulation totalled 50 ns. The results indicate that the mutations increase the dynamics of the flap, hinge, fulcrum and cantilever regions when compared to the wild-type protease while in complex with protease inhibitors. Specifically, these mutations result in the protease favouring the semi-open conformation when in complex with inhibitors. Moreover, the HP4 PR adopted curled flap tip conformers which coordinated several water molecules into the active site in a manner that may reduce inhibitor binding affinity. The mutations affected the thermodynamic landscape of inhibitor binding as there were fewer observable chemical contacts between the mutated variants and saquinavir, atazanavir and darunavir. These data help to elucidate the biophysical basis for the selection of cooperative non-active site mutations by the HI virus.

Keywords: Cooperative mutations; HIV Protease; Molecular dynamics; Non-active site mutations; South african subtype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Catalytic Domain
  • Drug Resistance, Viral
  • HIV Protease Inhibitors* / pharmacology
  • HIV Protease* / genetics
  • HIV Protease* / metabolism
  • Molecular Dynamics Simulation
  • Mutation

Substances

  • HIV Protease Inhibitors
  • HIV Protease